GlassScriptPhysician profile
Evan N Dunn
NPI 1972879484
$20,529.01
in general payments reported to CMS, 2019-2025
34 companies · $2,398 in 2025
The $2,398 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $702 · 2020: $5,072 · 2021: $2,115 · 2022: $2,171 · 2023: $2,251 · 2024: $5,819 · 2025: $2,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,017 · Consulting Fee: $1,850 · Travel and Lodging: $1,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,017.18 |
| Consulting Fee | $1,850.00 |
| Travel and Lodging | $1,601.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $5,327.70 | 2019-2025 | Eylea Hd, Eylea |
| Eyepoint US, INC. | $4,793.41 | 2020-2024 | |
| Alcon Vision LLC | $1,561.73 | 2021-2025 | Constellation, Unity, Total30 |
| Harrow Eye, LLC | $1,409.36 | 2023-2025 | Triesence, Iheezo |
| Astellas Pharma US INC | $1,130.39 | 2023-2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $784.28 | 2020-2021 | |
| Genentech USA, INC. | $707.08 | 2019-2025 | Vabysmo, Lucentis, Susvimo |
| Notal Vision, INC. | $649.73 | 2022-2024 | Foresee Home |
| Alimera Sciences, INC. | $486.31 | 2019-2024 | Iluvien, Yutiq |
| Horizon Therapeutics Plc | $447.86 | 2021-2023 | Tepezza |
| Allergan, INC. | $344.96 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $341.54 | 2022-2025 | Syfovre |
| Abbvie INC. | $278.82 | 2022-2025 | Ozurdex |
| Mallinckrodt Hospital Products INC. | $272.25 | 2021-2024 | Acthar |
| Glaukos Corporation | $255.81 | 2023-2024 | Idose |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $217.59 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $179.55 | 2019-2021 | |
| Rxsight INC | $167.81 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| New World Medical,INC. | $141.97 | 2020 | |
| Bausch & Lomb Americas INC. | $134.76 | 2022 | |
| Kala Pharmaceuticals, INC. | $124.99 | 2021 | |
| Dompe US, INC. | $120.97 | 2025 | Oxervate |
| Sight Sciences, INC. | $120.15 | 2022 | |
| Coherus Oncology, INC. | $99.04 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $88.58 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $83.73 | 2022 | |
| Ocular Therapeutix, INC. | $76.77 | 2023 | Dextenza |
| Ani Pharmaceuticals, INC. | $67.96 | 2025 | Iluvien, Yutiq |
| Sandoz INC. | $42.70 | 2024-2025 | Cimerli |
| Neurotech Pharmaceuticals, INC. | $28.62 | 2025 | |
| Biogen, INC. | $27.06 | 2023 | |
| Rayner Intraocular Lenses Limited | $15.53 | 2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.